Dr. Robert Melamede, CEO, Cannabis Science, Presents at World AIDS Institute Legislative Briefing

  Dr. Robert Melamede, CEO, Cannabis Science, Presents at World AIDS Institute
  Legislative Briefing

     Advancing the development of CS-TATI-1, Dr. Melamede presents before
  congressional staffers on the utility of phytocannabinoids to inhibit the
                            expression of HIV TAT

Business Wire

COLORADO SPRINGS, Colo. -- July 23, 2012

Cannabis Science Inc., (CBIS) on Friday, July 20th Robert Melamede PhD, CEO of
Cannabis Science presented at the Treatment Horizons Briefing at the Rayburn
Legislative Office Building in Washington D.C, sponsored by Rep. Danny Davis
(D-IL) and Rep Bobby Rush (D-IL) for an audience of congressional staffers on
the utility of CS-TATI-1, a unique antiviral approach to reduce the expression
of viral diversity undermining the efficacy of HART through out global
treatment programs.

Dr. Melamede states, “Cannabis Science is very appreciative of the opportunity
to present the clinical premise supporting the development of CS-TATI-1 to
address the application of CNR1 and CNR2 agonists and antagonists of HIV Tat
expression inhibitors to legislative staffers of ranking Members of Congress
directly preceding the opening of the XIX International AIDS Conference,” said
Dr. Melamede. “The clinical advancement of the indirect inhibition of HIV Tat
and subsequent corresponding pandemic co-infections that promote the
oncogenesis of HIV related malignancies is essential to avert the pathogenesis
of minority subspecies from highly conserved sanctuary regions.”

“It's a very important for the further development of CS-TATI-1 to provoke
legislative interest in CS-TATI-1 to ensure federal facilitation of further
development of the clinical advancement of research necessary for the
commercialization of CNR1 and CNR2 agonists and antagonists of HIV Tat
expression inhibitors,” said Mariel Selbovitz, MPH. VP of Research Program
Development at Cannabis Science. “Providing this essential clinical briefing
to Congressional staffers at the World AIDS Institute legislative briefing has
afforded Cannabis Science the opportunity to obtain support for a federal
initiative that will advance CS-TATI-1 to first human dosing.”

About CS-TAT-1

Data published in March by researchers at the Mount Sinai School of Medicine
found that phytocannabinoids inhibit TAT induced migration to TAT via CNR2
signal transduction. Funding for the Mount Sinai study was provided by a
National Institutes of Health (NIH) Clinical and Translational Science Award
Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly
diagnosed patients infected with drug resistant virus, treatment experienced
patients with drug-resistant HIV strains, and those intolerant of currently
available therapies. Cannabis Science will be pursuing a wide range of NIH
based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to
support preclinical development of target validation and proof of concept
studies. These studies will be implemented through collaborations with leading
scientific institutions. Cannabis Science will also be pursuing other clinical
research collaborations including the AIDS Clinical Trials Groups (ACTG), the
Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About HIV

HIV’s ability to mutate and reproduce itself even in the presence of
antiretroviral drugs, has led to a growing rate of drug resistance. Increasing
drug resistance is severely limiting treatment options for HIV patients around
the world, increasing direct and indirect health costs, furthering the spread
of drug resistant strains of HIV and is creating a pressing need to develop
new HIV drugs.

The U.S. government invests billions of dollars a year in HIV/AIDS research,
treatment and care through a variety of programs. The Ryan White CARE Act,
which funds the treatment and care of people living with HIV in the U.S.,
totals $2.3 billion a year. Among its many other contributions to fighting
HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S.
Military HIV Research Program and approximately $1 billion per year to The
Global Fund to Fight AIDS, Tuberculosis and Malaria.

Pharmaceutical sales to treat HIV equal $10.6 billion annually. Treatment cost
per patient in the U.S. for HIV antivirals alone is approximately $15,000 a
year.

About the XIX International AIDS Conference

The XIX International AIDS Conference is taking place July 22-27, 2012 in
Washington, DC. Bringing together leading researchers, clinicians, policy
makers and advocates, this momentous conference presents and affords
discussion on the latest scientific advances in HIV/AIDS.

About The World AIDS Institute

The World AIDS Institute documents and preserves the global history of
HIV/AIDS, inspires action today to improve the lives of people living with HIV
and their families, friends and communities, and strengthens the spectrum of
innovative initiatives to find a cure.

About Cannabis Science, Inc.

Cannabis Science, Inc. is conducting cannabinoid research and development for
unmet medical needs. The Company works with leading experts in HIV drug
development, medicinal characterization, and clinical research to develop,
produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a
Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical
cannabis-based preparations for the treatment of basal and squamous cell
carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Act of 1934. A statement containing works such as “anticipate,” “seek,”
intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or
similar phrases may be deemed “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Some or all of the
events or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences include the
future U.S. and global economies, the impact of competition, and the Company’s
reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor
does it intend to update the results of these forward-looking statements.

Contact:

Cannabis Science, Inc.
Dr. Robert J. Melamede
President and CEO
(888) 889-0888
info@cannabisscience.com
or
Robert Kane
VP of Investor Relations
(561) 234-6929
rkane@cannabisscience.com
www.cannabisscience.com